Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

Jocelyn and Kristofer Carella-Erickson detail their traumatic back-to-back cancer experiences with PEOPLE — and say their ...

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...

For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Tharimmune (THAR) announced preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...